What is Hematologics?
Hematologics is a recognized leader in Measurable Residual Disease (MRD) testing for acute leukemia, offering a comprehensive suite of diagnostic services. These include advanced techniques such as flow cytometry, next-generation sequencing, and cytogenetics, all aimed at providing accurate and timely analysis for hematologic malignancies. The company leverages cutting-edge methods like fluorescence in situ hybridization and molecular profiling to serve healthcare providers and clinical trial researchers. Hematologics is dedicated to enhancing patient outcomes through its specialized diagnostic solutions and expert analytical capabilities for myeloid and lymphoid neoplasms.
How much funding has Hematologics raised?
Hematologics has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Hematologics?
With its substantial backing and strategic investment, Hematologics is poised for significant growth and expansion. The company's focus on late-stage funding indicates a mature operational phase, likely geared towards enhancing its market penetration, expanding its service offerings, and potentially investing further in research and development to maintain its competitive edge in the rapidly evolving field of hematologic diagnostics. Future initiatives may involve broader adoption of its advanced MRD testing across clinical settings and research initiatives.
See full Hematologics company page
